AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
BASKING RIDGE, N.J., May 03, 2018 -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces that the Company will release financial results for the three months ended March 31, 2018 after close of the U.S. financial markets on Thursday, May 10, 2018.
Caladrius’ management will host a conference call for the investment community beginning at 4:30 p.m. ET on Thursday, May 10, 2018 to discuss the financial results, provide a company update and answer questions.
Shareholders and other interested parties may participate in the conference call by dialing (866) 595-8403 (domestic), or (706) 758-9979 (international), and providing conference ID: 9763239. The call will also be broadcast live on the Internet via the Company’s website at www.caladrius.com/investors/news-events.
For those unable to participate in the live conference call or webcast, a replay will be available beginning May 10, 2018 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 9763239.
The webcast will be archived on the Company’s website for 90 days.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in an ongoing Phase 2 trial. CLBS14, a CD34 cell therapy intended as a treatment for coronary microvascular dysfunction and refractory angina, is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is formulated specifically for intramuscular administration for the treatment of lower extremity ischemia. A phase 2 study of CLBS12 as a treatment for critical limb ischemia being conducted in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine regulations. For more information about Caladrius please visit www.caladrius.com.
Contacts:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Executive Director, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: [email protected]
LHA Investor Relations
Miriam Weber Miller
Senior Vice President
Phone: +1-212-838-3777
Email: [email protected]
